Literature DB >> 11642542

Modeling Huntington's disease in cells, flies, and mice.

S Sipione1, E Cattaneo.   

Abstract

A milestone in Huntington's disease (HD) research is represented by the identification of the causative gene. With the genetics at hand, a series of transgenic cellular and animal models has been developed, which has greatly contributed to understanding of HD. All these models are described in this review, and are compared to each other, along with the information they have generated. Although the mechanism by which progressive loss of striatal neurons occurs in HD remains uncertain, hypotheses on mutant huntingtin toxicity involve impaired vescicular trafficking, transcriptional dysregulation, and/or activation of apoptotic pathways. The development of inducible HD mice has shown that neurodegeneration in HD may be at least partially blocked. Although traditionally considered a "gain-of-function" disease, the recent finding that normal huntingtin has an important role in neuronal survival suggests that loss of function of the normal protein might contribute to HD as well, also discloseing new perspectives on the therapeutical approach to the pathology.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11642542     DOI: 10.1385/MN:23:1:21

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  185 in total

1.  Inhibition of polyglutamine protein aggregation and cell death by novel peptides identified by phage display screening.

Authors:  Y Nagai; T Tucker; H Ren; D J Kenan; B S Henderson; J D Keene; W J Strittmatter; J R Burke
Journal:  J Biol Chem       Date:  2000-04-07       Impact factor: 5.157

2.  Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain.

Authors:  M DiFiglia; E Sapp; K O Chase; S W Davies; G P Bates; J P Vonsattel; N Aronin
Journal:  Science       Date:  1997-09-26       Impact factor: 47.728

3.  Genotypes at the GluR6 kainate receptor locus are associated with variation in the age of onset of Huntington disease.

Authors:  D C Rubinsztein; J Leggo; M Chiano; A Dodge; G Norbury; E Rosser; D Craufurd
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

4.  HEAT repeats in the Huntington's disease protein.

Authors:  M A Andrade; P Bork
Journal:  Nat Genet       Date:  1995-10       Impact factor: 38.330

5.  Genetic suppression of polyglutamine toxicity in Drosophila.

Authors:  P Kazemi-Esfarjani; S Benzer
Journal:  Science       Date:  2000-03-10       Impact factor: 47.728

6.  Instability of highly expanded CAG repeats in mice transgenic for the Huntington's disease mutation.

Authors:  L Mangiarini; K Sathasivam; A Mahal; R Mott; M Seller; G P Bates
Journal:  Nat Genet       Date:  1997-02       Impact factor: 38.330

7.  Polyglutamine length-dependent interaction of Hsp40 and Hsp70 family chaperones with truncated N-terminal huntingtin: their role in suppression of aggregation and cellular toxicity.

Authors:  N R Jana; M Tanaka; G h Wang; N Nukina
Journal:  Hum Mol Genet       Date:  2000-08-12       Impact factor: 6.150

8.  Generation of neuronal intranuclear inclusions by polyglutamine-GFP: analysis of inclusion clearance and toxicity as a function of polyglutamine length.

Authors:  K L Moulder; O Onodera; J R Burke; W J Strittmatter; E M Johnson
Journal:  J Neurosci       Date:  1999-01-15       Impact factor: 6.167

9.  Widespread expression of Huntington's disease gene (IT15) protein product.

Authors:  A H Sharp; S J Loev; G Schilling; S H Li; X J Li; J Bao; M V Wagster; J A Kotzuk; J P Steiner; A Lo
Journal:  Neuron       Date:  1995-05       Impact factor: 17.173

10.  Juvenile Huntington disease.

Authors:  J G van Dijk; E A van der Velde; R A Roos; G W Bruyn
Journal:  Hum Genet       Date:  1986-07       Impact factor: 4.132

View more
  17 in total

Review 1.  Huntingtin in health and disease.

Authors:  Anne B Young
Journal:  J Clin Invest       Date:  2003-02       Impact factor: 14.808

Review 2.  Apoptotic cascades as possible targets for inhibiting cell death in Huntington's disease.

Authors:  Lindsay R Pattison; Mark R Kotter; Dean Fraga; Raphael M Bonelli
Journal:  J Neurol       Date:  2006-09-22       Impact factor: 4.849

Review 3.  High throughput screening for neurodegeneration and complex disease phenotypes.

Authors:  Hemant Varma; Donald C Lo; Brent R Stockwell
Journal:  Comb Chem High Throughput Screen       Date:  2008-03       Impact factor: 1.339

4.  Evidence for dynamic and multiple roles for huntingtin in Ciona intestinalis.

Authors:  Mohammed M Idris; Michael C Thorndyke; Euan R Brown
Journal:  Invert Neurosci       Date:  2013-12

Review 5.  Mutant huntingtin and mitochondrial dysfunction.

Authors:  Ella Bossy-Wetzel; Alejandra Petrilli; Andrew B Knott
Journal:  Trends Neurosci       Date:  2008-10-24       Impact factor: 13.837

Review 6.  Studying polyglutamine diseases in Drosophila.

Authors:  Zhen Xu; Antonio Joel Tito; Yan-Ning Rui; Sheng Zhang
Journal:  Exp Neurol       Date:  2015-08-06       Impact factor: 5.330

Review 7.  The cellular prion protein (PrP(C)): its physiological function and role in disease.

Authors:  Laura Westergard; Heather M Christensen; David A Harris
Journal:  Biochim Biophys Acta       Date:  2007-03-02

8.  Stimulation of NeuroD activity by huntingtin and huntingtin-associated proteins HAP1 and MLK2.

Authors:  Edoardo Marcora; Katherine Gowan; Jacqueline E Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-24       Impact factor: 11.205

9.  Novel BAC Mouse Model of Huntington's Disease with 225 CAG Repeats Exhibits an Early Widespread and Stable Degenerative Phenotype.

Authors:  Michal Wegrzynowicz; Terry Jo Bichell; Barbara D Soares; Meredith K Loth; Jennifer S McGlothan; Susumu Mori; Fatima S Alikhan; Kegang Hua; Jennifer M Coughlin; Hunter K Holt; Christopher S Jetter; Martin G Pomper; Alexander P Osmand; Tomás R Guilarte; Aaron B Bowman
Journal:  J Huntingtons Dis       Date:  2015

Review 10.  Magnetic resonance imaging of Huntington's disease: preparing for clinical trials.

Authors:  S Klöppel; S M Henley; N Z Hobbs; R C Wolf; J Kassubek; S J Tabrizi; R S J Frackowiak
Journal:  Neuroscience       Date:  2009-01-29       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.